Lineage Cell Therapeutics FY2024 EPS Raised by Cantor Fitzgerald

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Equities research analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for shares of Lineage Cell Therapeutics in a report released on Monday, November 18th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($0.14) per share for the year, up from their prior forecast of ($0.18). The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.11) per share.

Separately, Craig Hallum began coverage on shares of Lineage Cell Therapeutics in a research report on Tuesday, August 20th. They issued a “buy” rating and a $4.00 target price for the company.

Lineage Cell Therapeutics Stock Down 6.5 %

LCTX stock opened at $0.60 on Thursday. The stock has a market cap of $113.30 million, a price-to-earnings ratio of -5.00 and a beta of 1.28. Lineage Cell Therapeutics has a twelve month low of $0.56 and a twelve month high of $1.61.

Institutional Investors Weigh In On Lineage Cell Therapeutics

A number of institutional investors have recently made changes to their positions in LCTX. Raffles Associates LP lifted its position in Lineage Cell Therapeutics by 35.8% during the second quarter. Raffles Associates LP now owns 4,357,781 shares of the company’s stock valued at $4,346,000 after purchasing an additional 1,147,800 shares during the period. Bank of New York Mellon Corp lifted its position in Lineage Cell Therapeutics by 35.7% during the second quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock valued at $435,000 after purchasing an additional 114,762 shares during the period. Rhumbline Advisers lifted its position in Lineage Cell Therapeutics by 15.1% during the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after purchasing an additional 17,411 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock valued at $239,000 after purchasing an additional 70,418 shares during the period. Finally, Comerica Bank lifted its position in Lineage Cell Therapeutics by 84,745.8% during the first quarter. Comerica Bank now owns 250,295 shares of the company’s stock valued at $370,000 after purchasing an additional 250,000 shares during the period. Hedge funds and other institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.